anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The myHealth Rewards wellness program managed by GHP rewards those GHP members who carry their insurance through employment at Geisinger with reduced health insurance premiums over the course of the following year, if members register for the program and have their health measures on file by the enrollment deadline and are then able to meet their health goals by the respective due date. In spite of the potential savings to health plan members and the wellness program's potential to motivate engagement in healthy activities (with consequent improvement in health outcomes), about 23% of eligible existing GHP members did not enroll during the primary 2019 enrollment period, even after receiving promotional email communications and reminders. Therefore, the current study was developed to test whether a revised version of a standard welcome email is more effective than the standard email in increasing myHealth Rewards login and enrollment rates. The standard welcome email is what would typically be sent by GHP to encourage enrollment among new hires; it mentions the benefits of enrollment (maintaining good health and saving money on insurance premiums), the average premium savings, the ease of the registration process, and the deadline for registering and having health measures on file, plus it provides registration steps and hyperlinks for registering and finding free health screenings where health measures can be collected and registered at one convenient time and location. The loss frame email recommends that GHP members not "throw away" a precise monetary amount in savings by not participating and that they can therefore avoid missing out on substantial gains (i.e., savings) by taking action. It is hypothesized that, on average, the loss frame email will increase enrollment compared with the standard email, among this population of new hires for whom this is only the second time that they have been informed about myHealth Rewards. Findings will help inform how best to increase enrollment in a wellness program among health plan members who are new to the system.
Two adequate and well-controlled trials were performed in subjects with early Lyme disease. All subjects presented with physician-documented erythema migrans, with or without systemic manifestations of infection. Subjects were assessed at 1 month posttreatment for success in treating early Lyme disease (Part I) and at 1 year posttreatment for success in preventing the progression to the sequelae of late Lyme disease (Part II).

A total of 355 adult subjects (181 treated with cefuroxime axetil and 174 treated with doxycycline) were randomized in the 2 trials, with diagnosis of early Lyme disease confirmed in 79% (281/355). The clinical diagnosis of early Lyme disease in these subjects was validated by 1) blinded expert reading of photographs, when available, of the pretreatment erythema migrans skin lesion, and 2) serologic confirmation (using enzyme-linked immunosorbent assay [ELISA] and immunoblot assay ["Western" blot]) of the presence of antibodies specific to Borrelia burgdorferi, the etiologic agent of Lyme disease. The efficacy data in Table 11 are specific to this "validated" patient subset, while the safety data below reflect the entire patient population for the 2 trials. Clinical data for evaluable subjects in the "validated" patient subset are shown in Table 11.

Cefuroxime axetil and doxycycline were effective in prevention of the development of sequelae of late Lyme disease.

While the incidence of drug-related gastrointestinal adverse reactions was similar in the 2 treatment groups (cefuroxime axetil - 13%; doxycycline - 11%), the incidence of drug-related diarrhea was higher in the cefuroxime axetil arm versus the doxycycline arm (11% versus 3%, respectively).
The invention relates to a Chinese herbal medicine for curing hernia, which takes smallfruit rose root and sugar as principal agents, takes lanceolata as adjuvant toward the ischemia patients while takes astragalus as adjuvant toward gas-deprived patients, and takes astragalus and cimicifuga foetida as adjuvants toward Qi deficiency patients. The invention also relates to a preparation method. The invention takes root section of smallfruit rose root, and then removes raw bark and cuts short to sun-dry. The invention also takes root section of cimicifuga foetida, and then washes and cuts short to sun-dry. The invention overcomes the drawbacks of the current operative treatment and alleviative treatment of operation, incision, hospitalization, possible recrudescence, high charge and unconspicuous healing effect. After taking the invention, the effect of curing hernia is very good without operation and hospitalization, the charge is low. The Chinese herbal medicine can reduce the pain of the patients and economic burden, so is suitable for popularization and application.
OBJECTIVE: Understand the current situation and changing trends of low body weight in elderly population aged 60 years and above.
METHODS: Data was collected from 2002 Chinese Nutrition and Health Survey, 2010-2013 Chinese Nutrition and Health Surveillance and 2015 Chinese Adult Chronic Disease and Nutrition Surveillance. Multi-stage stratified cluster random sampling was used for all surveys or surveillance. In 2002, 27 778 samples of people aged 60 and over were taken from 132 monitoring sites in mainland China. In 2010-2013, 34 581 subjects were selected from 150 monitoring points in mainland China. In 2015, 59 576 subjects were selected from 302 monitoring points in mainland China. Questionnaires collected basic information such as gender, and date of birth, and information such as height and weight were collected through physical examination.
RESULTS: The prevalence of low body weight in the elderly aged 60 years and above showed a downward trend from 2002 to 2015 in China(P<0.01). The prevalence of low body weight decreased from 11.67% in 2002 to 5.19% in 2015. The prevalence of low body weight among males decreased from 11.51% in 2002 to 5.21% in 2015. The prevalence of low body weight among females decreased from 11.83% in 2002 to 5.17% in 2015. The prevalence of low body weight in the elderly aged 60 years and above showed an upward trend with age. The prevalence of low body weight in urban areas decreased from 5.85% in 2002 to 3.31% in 2015. The prevalence of low body weight in rural areas decreased from 16.25% in 2002 to 6.67% in 2015. The prevalence of low body weight in seven geographic regions of China decreased from 2002 to 2015. The prevalence of low body weight was highest in the elderly population aged 60 years and above in South China(9.49%(95%CI 8.61%-10.38%)) and lowest in North China(2.55%(95%CI 2.15%-2.95%)) in 2015.
CONCLUSION: The prevalence of low body weight among the elderly aged 60 years and above in China decreased from 2002 to 2015. The prevalence of low body weight increased with age. The prevalence was higher in rural areas than in urban areas, and the prevalence in South China was higher than in other geographic regions.
Patients use the WiseBag medication dispenser and receive personalized text message reminders, medication tracking and healthcare provider follow ups as part of the CONCURxP platform over 12 months. Patients may complete an interview over 20-30 minutes within 6 months of study completion.
Cpds. of formula (I), in which R is H, 1-4C alkyl or phenyl, and X is Cl, Br or I, are made by (a) reacting a cpd. of formula (II) with epichlorhydrin in presence of a base (b) reacting the prod. with isopropylamine to obtain a cpd. of formula (IV) (c) reacting this with an aldehyde RCHO to give an oxazolidine of formula (V) (d) reacting this with a cpd. of formula (VI) in presence of a base to obtain a cpd. of formula (VII) and (e) subjecting this to acid hydrolysis.
BACKGROUND: This research investigates quadriceps muscle fatigability (MF) in chronic obstructive pulmonary disease (COPD) patients with chronic respiratory failure (CRF) at different levels of lung obstruction [severe obstruction (SO)=FEV1 <50% and >30% versus very severe obstruction (VSO)=FEV1 ≤30%]. It explores the relationships between quadriceps MF and lung function, respiratory muscles, and oxygenation status.
METHODS: A post hoc cross-over analysis in 45 COPD patients (20 SO and 25 VSO) undergoing long-term oxygen therapy was performed. Delta change in quadriceps maximum voluntary contraction (MVC) (absolute value and percentage) before and after a constant workload was calculated. Associations between quadriceps MF and lung function, respiratory muscles, and gas exchange were examined using Pearson's correlation and multivariate linear regression analysis.
RESULTS: SO patients experience a more substantial reduction in MVC compared to VSO (-15.15±9.13% vs -9.29±8.90%, p=0.0357), despite comparable resting MVC. Dyspnea is more pronounced in VSO at the beginning and end of the exercise. Correlations were found between MF and maximal inspiratory pressure (MIP) (r=-0.4412, p=0.0056), maximal expiratory pressure (MEP) (r=-0.3561, p=0.0282), and a tendency for FEV1% (r=-0.2931, p=0.0507). The regression model (R2=0.4719) indicates that lower MIP and FEV1 and high total lung capacity are significant factors in reducing quadriceps muscle fatigability after a fatiguing task.
CONCLUSION: COPD patients with more severe pulmonary obstruction and hyperinflation and lower respiratory muscle strength have lower quadriceps MF but higher dyspnea both at rest and during exercise.
The participants receive placebo treatment. Patients assigned to the placebo treatment group will receive an intravenous infusion of 100 ml 0.9% NaCl solution at a rate of 15-25 drops/min for an IV infusion duration of more than 1 hour.
Dysphagia is a common complication after ACDF. PSTS is also a natural sequela of ACDF and can lead to airway compromise among other complications. Previous studies have demonstrated that administration of intravenous methylprednisolone (1mg/kg) after anterior cervical spine surgery reduced the incidence of pharyngolaryngeal lesions as identified by nasofibroscopic examination. Lee et al. prospectively evaluated 50 patients and determined that local application of steroids in the retropharyngeal area following ACDF reduced PSTS and odynophagia as measured by the Visual Analogue Scale (VAS) and the Neck Disability Index (NDI) compared to a control group. Furthermore, there were no adverse events/reactions from local application of steroid on a gel foam sponge in the setting of anterior spinal surgery. There are no studies in the current literature that investigate the incidence of dysphagia with application of local steroids after ACDF, nor are there any studies that stratify the efficacy of local steroids compared to intravenous steroids. There is also no current spine literature that directly compares the efficacy of intravenous steroids versus local steroids in the incidence of dysphagia or dysphonia. Our study will be the first in the literature to assess the efficacy of local steroids in reducing the incidence of dysphagia after anterior cervical spine surgery, and as a result, may improve patient outcomes after ACDF.

Dysphagia and dysphonia are common complications after anterior cervical spine surgery. Despite their clinical importance, studies on the treatment and/or prevention of these complications are limited due to the lack of valid and reliable outcome measures. The majority of research is found in the otolaryngology literature and has focused on disease pathophysiology, diagnosis, and therapy.

The Bazaz score has been used in the spine literature to evaluate dysphagia after anterior cervical discectomy and fusion (ACDF). This is a subjective questionnaire that has not been validated in the literature. Additionally, new patient-centered outcome measures, the Eating Assessment Tool (EAT-10) and Voice Handicap Index (VHI-10) have recently been developed, and in addition to the Bazaz score, have been shown to have excellent validity and reliability in the ENT patient population. These instruments can be used to document the initial dysphagia or dysphonia severity and monitor the treatment response in people with a wide array of swallowing and voice disorders.
Patients with advanced cancer frequently develop significant anemia, as determined by a blood test to measure hematocrit, with a below normal hematocrit of \<=37%. Agents that can elevate the hematocrit level in patients with advanced cancer may increase the physical strength and stamina that is decreased by anemia, increase the patients' ability to persevere with chemotherapy, and improve their overall quality of life. Epoetin alfa is a genetically engineered form of a natural hormone, erythropoietin, that is used to treat anemia by stimulating red blood cell production. This is a randomized, double-blind, placebo-controlled, parallel group, multicenter study to determine the safety and effectiveness of treatment with epoetin alfa in patients with persistent anemia caused by advanced cancer. Eligible patients will be randomly assigned to one of two treatment groups: epoetin alfa 100 units per kilogram or a comparable volume of placebo, given by injection beneath the skin. Patients will be given study medication 3 times weekly for up to 8 weeks or until a patient's hematocrit reaches 38% to 40%. The 8 weeks will be decreased to 4 weeks if, by Week 4, a patient's hematocrit decreases by more than 15% from the start of the study. At the end of the double-blind part of the study, patients who achieved a hematocrit level of 38 to 40%, or whose hematocrit decreased by \>=15% from the start of the study by Week 4, will be allowed to enroll in the open-label part of the study for an additional 6 months and will receive epoetin alfa at a dose adjusted to maintain a hematocrit level between 38% and 40%. Within 5 to 7 days after it is documented that a patient's hematocrit has reached 38% to 40%, epoetin alfa will then be given once weekly by injection beneath the skin to maintain the hematocrit between 38% and 40% for the remaining time of the study. Patients will be seen by a healthcare professional once weekly and by the physician once monthly. Safety evaluations will include changes in laboratory tests, vital signs, physical examinations, electrocardiograms, and the incidence of adverse events from the start of the study to the end of the double-blind part of the study and to the end of the open-label part of the study. Effectiveness will be assessed by blood transfusion requirements and changes in hemoglobin, hematocrit, and immature red blood cell count from the start of the study to the end of study, as well as the physician's global evaluation and the quality of life assessment at the end of the double-blind part of the study and at the end of the open-label part of the study. The study hypothesis is that epoetin alfa will be well tolerated and more effective than placebo in stimulating adequate production of red blood cells in patients who are anemic as a result of advanced cancer. Double-blind: Epoetin alfa 100 units/kilogram (U/kg) or placebo injected under the skin; given 3 times weekly for 8 weeks or until hematocrit reaches 38%-40%. Open-label: Epoetin alfa 100 or 150 U/kg or a higher dose injected under the skin on a schedule to maintain hematocrit of 38%-40%.
Participants randomized to the control arm will undergo symptom-based TB screening at study entry. Participants reporting ≥1 TB symptom (current cough, fever, night sweats, weight loss) will be regarded as screen-positive and will be referred for confirmatory TB testing, in accordance with WHO guidelines. Participants with none of the 4 TB symptoms will be regarded as screen-negative and will be assessed for TPT eligibility.
Five healthy subjects will be allocated to the single treatment group at a fixed dose of 6 μg/kg of IV PRTX-100. Subjects will receive four weekly doses. All subjects will have a serum collection requiring approximately 600 mL of blood. Since subjects will be followed for 28 days after their last dose, the total duration of the study is approximately 3 months. Subjects will be evaluated for adverse events and the development of anti-PRTX-100 antibodies. Adverse events will be evaluated for at least four weeks after the last dose of PRTX-100.
The invention relates to a felodipine sustained-release tablet and a preparation method thereof. The sustained-release tablet contains an effective amount of felodipine, polyvinylpyrrolidone K30 or polyvinylpyrrolidone K25, wherein the ratio of the polyvinylpyrrolidone K30 or polyvinylpyrrolidone K25 to the felodipine is 3 to 12 : 1, sustained-release materials and the like. The preparation method of the felodipine sustained-release tablet comprises the following steps: adding a solubiliser into an organic good solvent of felodipine for dissolution, and then adding the felodipine for completedissolution of the solubiliser; adding a prepared solution into a adsorbent mixture, and performing sieving and granulating; and then carrying out drying under a normal pressure to obtain sustained-release dry particles containing solubilized felodipine, and then carrying out granulating, tabletting, and coating to obtain a felodipine sustained-release tablet. According to the invention, the felodipine is solubilized, which enables the curative effect to be enhanced. Besides, a traditional hard-soluble medicament sustained-release tablet has complicated preparation process with high energy consumption, and is not easy to produce and uncontrollable in quality; however, the above problems are solved by the preparation method provided in the invention. Therefore, the simple, low-energy, and high-efficient industrialized production is allowed according to the invention.
The method for the surgical treatment of the diseases of parodontum provides for the anesthesia followed by the flap-like parodontal surgery with horizontal and vertical incisions. The vertical incisions are performed starting from the gingival edge to the length of the bone tissue destruction assessed by X-ray examination with the superposition of the marker for estimating the size of pathologic area prior to the surgery. The horizontal incisions are performed with maximal sparing of the festoon edge of the gums. Then the mucous-periosteal flap is separated providing for the operative access to the infected surface of the root with the bone pouches and the lesions of the branching area. Thecurettage of the bone pouches is performed, the granulation tissue is removed, the surface of the root is thoroughly cleaned under the visual control. In the areas of the unfavorable morphology of the alveolar bone or the tooth, the surgical correction is carried out. The blood plasma enriched in platelets is used for the regenerative surgery. The enriched plasma is prepared by mixing the blood plasma of the patient (1/3) with the platelet concentrate. The blood plasma enriched in platelets is used for filling the bone pouches and the gaps between the teeth. Moreover, blood plasma enriched in platelets is transferred from the vestibular and the oral surfaces to the alveolar process. Then the flaps are return to the original positions. Finally, the sutures are applied in each gap between the teeth.
Heterodimeric T cell receptor proteins, comprising α and β subunits joined by at least one disulfide bond, are disclosed. The α and β subunits are generated as chimeric polypeptides, utilizing z chains or constant regions of IgG1 as chimeric partners. Also disclosed are soluble heterodimeric T cell recpetor molecules with a conformation essentially indistinguishable from that appearing on the surface of T cells. The invention also concerns DNA encoding the heterodimeric TCR, transfer vectors comprising DNA encoding the heterodimeric TCR, and host cells containing such transfer vectors. In addition, the invention pertains to various uses of heterodimeric TCR. The proteins can be used in molecular assays designed to measure their binding to ligands, including MHC/HLA-peptide antigen complexes or TCR-specific antibodies. Such assays are useful for the detection of agents that block the TCR-ligand interaction. The heterodimeric TCR can also be used to immunize animals, including humans, to produce TCR-specific antibodies. In addition, either in their native or denatured conformation, the proteins can be used to vaccinate animals, including humans, in order to suppress the immune response of T cells bearing TCR that share antigenic epitopes with the vaccinating protein.
PURPOSE:To uniformly obtain a large amt. of tetracalcium phosphate by the method of calcinating calcium hydrogenphosphates with specified proportions or a compounded material of calcium pyrophosphate and calcium carbonate by pulverizing and mixing the compounded material in a wet state. CONSTITUTION:Calcium hydrogenphosphates or its dihydrate, or calcium pyrophosphate and calcium carbonate are compounded so as to obtain the molar ratio of Ca/P=2 and mixed by wet pulverization with using water a a mixing medium. For example, a pulverization tank 2 is filled with lots of pulverizing balls 4, into which the source slurry 6 is introduced and stirred with the balls forcedly by an agitating means 8. The obtd. mixture powder is then calcinated. By this method, production of apatite or CaO can be suppressed and single phase of tetracalcium phosphate can be obtd. in a shorter calcination time and mixing time.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to surgery, can be used to accelerate the healing of postoperative foot wounds, activate local immunity, increasing regenerative activity of involved tissues, preventing microthrombosis of peripheral arterial bed in patients with purulonecrotic complications of diabetic foot syndrome. Treatment is conducted in three phases. At the first stage, the wound of the foot is sealed from the external environment by the application of a sterile sponge and an adhesive film, constant negative pressure of 100 mm Hg is created above the wound with the port and VIT Medical portable vacuum aspiration device for 10 days. Simultaneously, drug-induced treatment is carried out, including intravenous drop introduction of Vessel DUE F 600 LE per 200 ml of 0.9 % sodium chloride solution per day, introduction of Vasaprostan 60 mcg once a day intravenously drop-by-drop on 200 ml of 0.9 % sodium chloride solution and oral administration of Trombovazim 800 units twice a day. At the second stage, oscillations of negative pressure over the wound are created by automatic change of the pressure level from 100 to 20 mm Hg and back, with change of 20 mm Hg per hour during a day for six to eight days. At the same time, Vessel DUE F 250 LE 1 capsule is taken orally twice a day, Trombovazim 800 units twice a day. At the third stage, the local foot wound treatment is performed with the "G-Derm" histoequivalent-bioplastic material with a dressing interval of two to three days, which is moistened twice a day with 0.9 % sodium chloride solution, in a combination with oral administration of Vessel DUE F 250 LE 1 capsule twice a day with a total course of 8 weeks, oral administration of Trombovazim 800 units twice a day with a total course of twenty days. After completing receiving Trombovazim oral administration of Xarelto 2.5 mg twice a day, course 12-24 weeks.EFFECT: method enables higher effectiveness and reduced length of treatment of patients with purulonecrotic complications of diabetic foot syndrome ensured by a combination of methods of the declared method.1 cl, 1 ex